Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XP4A
|
|||
| Former ID |
DNCL002737
|
|||
| Drug Name |
Labetuzumab I-131
|
|||
| Synonyms |
IMMU-111
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
Immunomedics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [2], [3] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol.2005 Sep 20;23(27):6763-70. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 692828). | |||
| REF 3 | Clinical pipeline report, company report or official report of Immunomedics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.